Synthesis of novel potent hepatitis C virus NS3 protease inhibitors: Discovery of 4-hydroxy-cyclopent-2-ene-1,2-dicarboxylic acid as a N-acyl-l-hydroxyproline bioisostere

Bioorganic and Medicinal Chemistry

Volumn 15, Issue 2, 2007, Pages 827-838

  Thorstensson, Fredrik ^a   Wångsell, Fredrik ^a   Kvarnström, Ingemar ^a   Vrang, Lotta ^b   Hamelink, Elizabeth ^b   Jansson, Katarina ^b   Hallberg, Anders ^c   Rosenquist, Åsa ^a,b   Samuelsson, Bertil ^b,d  

^a LINKÖPING UNIVERSITY   (Sweden)

^b MEDIVIR AB   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d STOCKHOLM UNIVERSITY   (Sweden)

Author keywords

4 Hydroxy cyclopent 2 ene 1,2 dicarboxylic acid; Cyclopentene; HCV; N Acyl l hydroxyproline mimic; NS3; Protease inhibitor

Indexed keywords

2 [[2 [1 [(CYLOHEXYLMETHOXYCARBONYLMETHYL)CARBAMOYL] 2,2 DIMETHYLPROPYLCARBAMOYL] 4 (7 METHOXY 2 PHENYLQUINOLIN 4 YLOXY)CYCLOPENT 2 ENECARBONYL]AMINO]PENTANOIC ACID; 2 [[2 [1 [(CYLOHEXYLMETHOXYCARBONYLMETHYL)CARBAMOYL] 2,2 DIMETHYLPROPYLCARBAMOYL] 4 (7 METHOXY 2 PHENYLQUINOLIN 4 YLOXY)CYCLOPENT 2 ENECARBONYL]AMINO]PENTANOIC ACID TERT BUTYL ESTER; 4 HYDROXY CYCLOPENT 2 ENE 1,2 DICARBOXYLIC ACID; AMINO ACID DERIVATIVE; ANTIVIRUS AGENT; HYDROXYL GROUP; HYDROXYPROLINE; PROTEINASE INHIBITOR; QUINOLINOL DERIVATIVE;

ARTICLE; DRUG POTENCY; DRUG SYNTHESIS; HEPATITIS C VIRUS; IN VITRO STUDY; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

CYCLOPENTANES; DICARBOXYLIC ACIDS; INDICATORS AND REAGENTS; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; PROTEASE INHIBITORS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS;

EID: 33845320743     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2006.10.044     Document Type: Article

References (74)

1. Choo Q.L., Kuo G., Weiner A.J., Overby L.R., Bradley D.W., and Houghton M. Science 244 (1989) 359-362
2. Kuo G., Choo Q.L., Alter H.J., Gitnick G.L., Redeker A.G., Purcell R.H., Miyamura T., Dienstag J.L., Alter M.J., and Stevens C.E. Science 244 (1989) 362-364
3. Di Bisceglie A.M., and Hepatitis C. Lancet 351 (1998) 351-355
4. WHO fact sheet N°164. Revised October 2000. http://www.who.int/mediacentre/factsheets/fs164/en/index.html/.
5. Freeman A.J., Dore G.J., Law M.G., Thorpe M., Overbeck J.O., Lloyd A.R., Marinos G., and Kaldor J.M. Hepatology 34 (2001) 809-816
6. Willems M., Metselaar H.J., Tilanus H.W., Schalm S.W., and de Man R.A. Transpl. Int. 15 (2002) 61-72
7. Cheng S.J., Bonis P., Lau J., Pham N.Q., and Wong J.B. Hepatology 33 (2001) 231-240
8. Tan S.-L., Pause A., Shi Y., and Sonenberg N. Nat. Rev. Drug Discov. 1 (2002) 867-881
9. Di Bisceglie A.M., McHutchison J., and Rice C.M. Hepatology 35 (2002) 224-231
10. Herrmann E., Lee J.H., Marinos G., Modi M., and Zeuzem S. Hepatology 37 (2003) 1351-1358
11. Reed K.E., and Rice C.M. Curr. Top. Microbiol. Immunol. 242 (2000) 55-84
12. Kolykhalov A.A., Mihalik K., Feinstone S.M., and Rice C.M. J. Virol. 74 (2000) 2046-2051
13. Gordon C.P., and Keller P.A. J. Med. Chem. 48 (2005) 1-20
14. Rosenberg S. J. Mol. Biol. 313 (2001) 451-464
15. De Francesco R., Tomei L., Altamura S., Summa V., and Migliaccio G. Antiviral Res. 58 (2003) 1-16
16. Griffith R.C., Lou L., Roberts C.D., and Schm U. Annu. Rep. Med. Chem. 39 (2005) 223-237
17. Ni Z.-J., and Wagman A.S. Curr. Opin. Drug Discov. Dev. 7 (2004) 446-459
18. Goudreau N., and Llinàs-Brunet M. Expert Opin. Investig. Drugs 14 (2005) 1129-1144
19. Malcolm B.A., Liu R., Lahser F., Agrawal S., Belanger B., Butkiewicz N., Chase R., Gheyas F., Hart A., Hesk D., Ingravallo P., Jiang C., Kong R., Lu J., Pichardo J., Prongay A., Skelton A., Tong X., Venkatraman S., Xia E., Girijavallabhan V., and Njoroge F.G. Antimicrob. Agents Chemother. 3 (2006) 1013-1020
20. Yi M., Tong X., Skelton A., Chase R., Chen T., Prongay A., Bogen S.L., Saksena A.K., Njoroge F.G., Veselenak R.L., Pyles R.B., Bourne N., Malcolm B.A., and Lemon S.M. J. Bio. Chem. 281 (2006) 8205-8215
21. Tong X., Chase R., Skelton A., Chen T., Wright-Minogue J., and Malcolm B.A. Antivir. Res. 70 (2006) 28-38
22. http://www.vrtx.com/. News may 17 2005: Vertex reports that oral hepatitis C protease inhibitor, VX-950, dramatically reduces viral levels in phase Ib clinical study.
23. Shu-Hui C., Lamar J., Yip Y., Frantz V., Johnson R.B., Wang Q.M., Glass J.I., Heinz B., and Colacino J. Lett. Drug Des. Discovery 2 (2005) 118-124
24. Lin C., Lin K., Luong Y.-P., Rao B.G., Wei Y.-Y., Brennan D.L., Fulghum J.R., Hsiao H.-M., Ma S., Maxwell J.P., Cottrell K.M., Perni R.B., Gates C.A., and Kwong A.D. J. Biol. Chem. 279 (2004) 17508-17514
25. Yip Y., Victor V., Lamar J., Johnson R., Wang Q.M., John D.B., Ling G., Lifei J., Daryl L., Wakulchik V.M., Xie C., Heinz B., Villarreal E., Colacino J., Yumibe N., Tebbe M., Munroe J., and Chen S.-H. Bioorg. Med. Chem. Lett. 14 (2004) 251-256
26. Schechter I., and Berger A. Biochem. Biophys. Res. Commun. 27 (1967) 157-162
27. Llinàs-Brunet M., Bailey M., Fazal G., Goulet S., Halmos T., Laplante S., Maurice R., Poirier M., Poupart M.-A., Thibeault D., Wernic D., and Lamarre D. Bioorg. Med. Chem. Lett. 8 (1998) 1713-1718
28. LaPlante S.R., Cameron D.R., Aubry N., Lefebvre S., Kukolj G., Maurice R., Thibeault D., Lamarre D., and Llinàs-Brunet M. J. Biol. Chem. 274 (1999) 18618-18624
29. Llinàs-Brunet M., Bailey M., Fazal G., Ghiro E., Gorys V., Goulet S., Halmos T., Maurice R., Poirier M., Poupart M.-A., Rancourt J., Thibeault D., Wernic D., and Lamarre D. Bioorg. Med. Chem. Lett. 10 (2000) 2267-2270
30. Beaulieu P.L., and Llinàs-Brunet M. Curr. Med. Chem. 1 (2002) 163-176
31. Llinàs-Brunet M., Bailey M.D., Bolger G., Brochu C., Faucher A.-M., Ferland J.M., Garneau M., Ghiro E., Gorys V., Grand-Maître C., Halmos T., Lapeyre-Paquette N., Liard F., Poirier M., Rhéaume M., Tsantrizos Y.S., and Lamarre D. J. Med. Chem. 47 (2004) 1605-1608
32. Llinàs-Brunet M., Bailey M.D., Ghiro E., Gorys V., Halmos T., Poirier M., Rancourt J., and Goudreau N. J. Med. Chem. 47 (2004) 6584-6594
33. Tsantrizos Y.S., Bolger G., Bonneau P., Cameron D.R., Goudreau N., Kukolj G., LaPlante S.R., Llinàs-Brunet M., Nar H., and Lamarre D. Angew. Chem. Int. Ed. Engl. 42 (2003) 1356-1360
34. Lamarre D., Anderson P.C., Bailey M., Beaulieu P., Bolger G., Bonneau P., Bös M., Cameron D.C., Cartier M., Cordingley M.G., Faucher A.-M., Goudreau N., Kawai S.H., Kukolj G., Lagacé L., LaPlante S.R., Narjes H., Poupart M.-A., Rancourt J., Sentjens R.E., St. George R., Simoneau B., Steinmann G., Thibeault D., Tsantrizos Y.S., Weldon S.M., Yong C.-L., and Llinàs-Brunet M. Nature 426 (2003) 186-189
35. Faucher A.-M., Bailey M.D., Beaulieu P.L., Brochu C., Duceppe J.-S., Ferland J.-M., Ghiro E., Gorys V., Halmos T., Kawai S.H., Poirier M., Simoneau B., Tsantrizos Y.S., and Llinàs-Brunet M. Org. Lett. 6 (2004) 2901-2904
36. Reiser M., Hinrichsen H., Benhamou Y., Reesink H.W., Wedemeyer H., Avendano C., Riba N., Yong C.-L., Nehmiz G., and Steinmann G.G. Hepatology 41 (2005) 832-835
37. See, for example:. Nöteberg D., Brånalt J., Kvarnström I., Classon B., Samuelsson B., Nillroth U., Danielsson U.H., Karlén A., and Hallberg A. Tetrahedron 53 (1997) 7975-7984
38. See, for example:. Turbanti L., Cerbai G., Di Bugno C., Giorgi R., Garzelli G., Criscuoli M., Renzetti A.R., Subissi A., Bramati G., and DePriest S.A. J. Med. Chem. 36 (1993) 699-707
39. See, for example:. Das J., and Kimball S.D. Bioorg. Med. Chem. 3 (1995) 999-1007
40. Nöteberg D., Brånalt J., Kvarnström I., Linschoten M., Musil D., Nyström J.E., Zuccarello G., and Samuelsson B. J. Med. Chem. 43 (2000) 1705-1713
41. Thorstensson F., Kvarnström I., Musil D., Nilsson I., and Samuelsson B. J. Med. Chem. 46 (2003) 1165-1179
42. Johansson P.-O., Bäck M., Kvarnström I., Vrang L., Hamelink E., Hallberg A., Rosenquist Å., and Samuelsson B. Bioorg. Med. Chem. 14 (2006) 5136-5151
43. Molander G.A., Quirmbach M.S., Silva L.F., Spencer K., and Balsells J. Org. Lett. 3 (2001) 2257-2260
44. Rosenquist Å., Kvarnström I., Svensson S.C.T., Classon B., and Samuelsson B. Acta Chem. Scand. 46 (1992) 1127
45. Dolby L.J., Esfandiari S., Elliger C.A., and Marshall K.S. J. Org. Chem. 36 (1971) 1277-1285
46. 3 or PhSeBr/LDA followed by oxidation, resulted unfortunately in racemization. For synthesis of (1R,2R)-4 see Ref. 17b. For the elimination conditions using PhSeBr we followed the procedure used in:. Wachtmeister J., Claesson B., Samuelsson B., and Kvarnström I.. Tetrahedron 51 (1995) 2029-2038
47. The syn-6 was purified by flash chromatography. Unfortunately the anti-6 was always strongly contaminated by syn-6. Pure anti-6 was synthesized from syn-6 by the use of the Mitsunobu inversion reaction. See the experimental section for further information.
48. Supporting Information.
49. Honda M., Hirata K., Sueoka H., Katsuki T., and Yamaguchi M. Tetrahedron Lett. 22 (1981) 2679-2681
50. Llinàs-Brunet, M.; Bailey, M. D.; Cameron, D.; Faucher, A.-M.; Ghiro, E.; Goudreau, N.; Halmos, T.; Poupart, M.-A.; Rancourt, J.; Tsantrizos, Y. S.; Wernic, D. M.; Simoneau, B.; WO 00/09543, 24 February 2000.
51. Tsantrizos, Y. S.; Cameron, D. R.; Faucher, A.-M.; Ghiro, E.; Goudreau, N.; Halmos, T.; Llinàs-Brunet, M. WO 00/59929, 12 October 2000.
52. Park K.-H., Olmstead M.M., and Kurth M.J. J. Org. Chem. 63 (1998) 6579-6585
53. Pearson D.A., Lister-James J., McBride W.J., Wilson D.M., Martel L.J., Civitello E.R., and Dean R.T. J. Med. Chem. 39 (1996) 1372-1382
54. Carpino L.A., and Han G.Y. J. Org. Chem. 22 (1972) 3404-3409
55. Thierry J., Yue C., and Potier P. Tetrahedron Lett. 39 (1998) 1557-1560
56. Beaulieu P.L., Gillard J., Bailey M.D., Boucher C., Duceppe J.-S., Simoneau B., Wang X.-J., Zhang L., Grozinger K., Houpis I., Farina V., Heimroth H., Krueger T., and Schnaubelt J. J. Org. Chem. 70 (2005) 5869-5879
57. Mitsunobu O., and Yamada M. Bull. Chem. Soc. Jpn. 40 (1967) 2380-2382
58. Freidinger R.M., Hinkle J.S., Perlow D.S., and Arison B.H. J. Org. Chem. 48 (1983) 77-81
59. Mehta A., Jaouhari R., Benson T.J., and Douglas K.T. Tetrahedron Lett. 33 (1992) 5441-5444
60. See experimental section for specific information.
61. Energy minimization was done in DS ViewerPro Suite (2002) and Chemdraw 3D (2004). Both programs confirmed distance differences between the 14a and 14b isomers.
62. The NOESY spectra of the two diastereomers as well as the ROESY spectra exhibited similar NOE cross-peak patterns and intensities except at the cross-peak P2Hα ↔ P3NH.
63. Goudreau N., Dale R., Bonneau C.R., Plouffe V.G.C., Poirier M., Lamarre D., and Llinàs-Brunet M. J. Med. Chem. 47 (2004) 123-132
64. Orvieto F., Koch U., Matassa V.G., and Muraglia E. Bioorg. Med. Chem. Lett. 13 (2003) 2745-2748
65. Barbato G., Cicero D.O., Cordier F., Narjes F., Gerlach B., Sambucini S., Grzesiek S., Matassa V.G., De Franscesco R., and Bazzo R. EMBO J. 6 (2000) 1195-1206
66. Yao N., Reichert P., Taremi S.S., Prosise W.W., and Weber P.C. Structure 7 (1999) 1353-1363
67. Johansson A., Hubatsch I., Åkerblom E., Lindeberg G., Winiwarter S., Danielsson U.H., and Hallberg A. Bioorg. Med. Chem. Lett. 11 (2001) 203-206
68. Johansson A., Poliakov A., Åkerblom E., Lindeberg G., Winiwarter S., Samuelsson B., Danielsson U.H., and Hallberg A. Bioorg. Med. Chem. 12 (2002) 3915-3922
69. Rancourt J., Cameron D.R., Gorys V., Lamarre D., Poirier M., Thibeault D., and Llinàs-Brunet M. J. Med. Chem. 47 (2004) 2511-2522
70. Frantz V., Lamar J., Snyder N., Yip Y., Guo D., Yumibe N., Johnson R.B., Wang Q.M., Glass K.J.I., and Chen S.-H. Biorg. Med. Chem. Lett. 14 (2004) 257-261
71. 19 were truncated.
72. i values they failed to show any significant activity when tested in the subgenomic HCV replicon cell-based assay.
73. The enzyme inhibition assays were performed by Professor Pei Zhen Tao at The Department of Virology, Institute of Medicinal Technology, Beijing, China.
74. Poliakov A., Hubatsch I., Schuman C.F., Stenberg G., and Danielsson U.H. Protein Expr. Purif. 25 (2002) 363-371